Affinity reagents against tumour-associated extracellular molecules and newforming vessels

Advanced Drug Delivery Reviews

Volumn 31, Issue 1-2, 1998, Pages 43-52

  Neri, Dario ^a   Zardi, Luciano ^b  

^a ETH ZURICH   (Switzerland)

^b UNIVERSITY OF GENOA   (Italy)

Author keywords

Alternative splicing; Angiogenesis; Clinical application of novel tumour targeting agents; Fibronectin; Recombinant antibodies; Tenascin

Indexed keywords

AGENTS; ANTIBODIES; ONCOLOGY;

ANGIOGENESIS; FIBRONECTIN; TENASCIN;

CONTROLLED DRUG DELIVERY;

FIBRONECTIN; MESSENGER RNA; MONOCLONAL ANTIBODY; RECOMBINANT PROTEIN; TENASCIN; TUMOR ANTIGEN;

ALTERNATIVE RNA SPLICING; ARTICLE; CANCER IMMUNOTHERAPY; EXTRACELLULAR MATRIX; HUMAN; NONHUMAN; PRIORITY JOURNAL; STROMA; TARGET ORGAN; TUMOR VASCULARIZATION;

EID: 0032489807     PISSN: 0169409X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0169-409X(97)00093-8     Document Type: Review

References (85)

1. Folkman J. Angiogenesis in cancer, vascular, rheumatoid and other disease. Nature Med. 1:1995;27-31.
2. Van den Hoff A. Stromal involvement in malignant growth. Adv. Cancer Res. 50:1988;159-196.
3. Risau W., Lemmon V. Changes in the vascular extracellular matrix during embryonic vasculogenesis and angiogenesis. Dev. Biol. 125:1988;441-450.
4. Ingber D., Folkman J. How does extracellular matrix control capillary morphogenesis? Cell. 58:1989;803-805.
5. Borsi L., Carnemolla B., Nicolò G., Spina B., Tanara G., Zardi L. Expression of different tenascin isoforms in normal, hyperplastic and neoplastic human breast tissues. Int. J. Cancer. 52:1992;688-692.
6. Carnemolla B., Balza E., Siri A., Zardi L., Nicotra M.R., Bigotti A., Natali P.G. A tumor-associated fibronectin isoform generated by alternative splicing of messenger RNA precursors. J. Cell Biol. 108:1989;1139-1148.
7. Castellani P., Viale G., Dorcaratto A., Nicolò G., Kaczmarek J., Querzé G., Zardi L. The fibronectin isoform containing the ED-B oncofetal domain: a marker of angiogenesis. Int. J. Cancer. 59:1994;612-618.
8. Kaczmarek J., Castellani P., Nicolò G., Spina B., Alemanni G., Zardi L. Distribution of oncofetal fibronectin isoforms in normal, hyperplastic and neoplastic human breast tissues. Int. J. Cancer. 58:1994;11-16.
9. Leprini A., Querzè G., Zardi L. Tenascin isoforms: possible targets for diagnosis and therapy of cancer and mechanisms regulating their expression. Perspect. Dev. Neurobiol. 2:1994;117-123.
10. Balza E., Borsi L., Allemanni G., Zardi L. Transforming growth factor-b regulates the levels of different fibronectin isoforms in normal human cultured fibroblasts. FEBS Lett. 228:1988;42-44.
11. Borsi L., Castellani P., Risso A.M., Leprini A., Zardi L. Transforming growth factor-b regulates the splicing pattern of fibronectin messenger RNA precursor. FEBS Lett. 261:1990;175-178.
12. Shifrin V.I., Neel B.G. Growth factor-inducible alternative splicing of non-transmembrane phosphotyrosine phosphatase PTP-1B pre-mRNA. J. Biol. Chem. 268:1993;25376-25384.
13. Borsi L., Balza E., Castellani P., Carnemolla B., Ponassi M., Querzé G., Zardi L. Cell-cycle dependent alternative splicing of the tenascin primary transcript. Cell Adhes. Commun. 1:1994;307-317.
14. Borsi L., Balza E., Gaggero B., Allemanni G., Zardi L. The alternative splicing pattern of the tenascin-C pre-mRNA is controlled by the extracellular pH. J. Biol. Chem. 11:1995;6243-6245.
15. Bourdon M.A., Wikstrand C.J., Furthmayr H., Matthews T.J., Bigner D.D. Human glioma-mesenchymal extracellular matrix antigen defined by monoclonal antibody. Cancer Res. 43:1983;2796-2805.
16. Riva P., Arista A., Sturiale C., Moscatelli G., Tison V., Mariani M., Seccamani E., Lazzari S., Fagioli L., Franceschi G., Sarti G., Riva N., Natali P.G., Zardi L., Scassellati G.A. Treatment of intracranial human glioblastoma by direct intratumoral administration of 131 I-labelled anti-tenascin monoclonal antibody BC-2. Int. J. Cancer. 51:1992;1-7.
17. Bourdon M.A., Coleman R.E., Blasberg R.G., Groothius D.R., Bigner D.D. Monoclonal antibody localization in subcutaneous and intracranial human glioma xenografts: paired-label and imaging analysis. Anticancer Res. 4:1984;133-140.
18. Bullard D.E., Adams C.J., Coleman R.E., Bigner D.D. In vivo imaging of intracranial human glioma xenografts comparing specific with non-specific radiolabeled monoclonal antibodies. J. Neurosurg. 64:1986;257-262.
19. 131I-radiolabelled murine monoclonal antibody in a human glioma xenograft model. Cancer Res. 48:1988;559-566.
20. 131I-labeled anti-tenascin monoclonal antibody 81C6. Cancer Res. 48:1988;2904-2910.
21. Schold S.C. Jr., Zalutsky M.R., Coleman R.E., Glantz M.J., Friedman A.H., Jaszczak R.J., Bigner S.H., Bigner D.D. Distribution and dosimetry of I-123-labeled monoclonal antibody 81C6 in patients with anaplastic glioma. Invest. Radiol. 28:1993;488-496.
22. He X., Archer G.E., Wikstrand C.J., Morrison S.L., Zalutsky M.R., Bigner D.D., Batra S.K. Generation and characterization of a mouse/human chimeric antibody directed against extracellular matrix protein tenascin. J. Neuroimmunol. 52:1994;127-137.
23. Balza E., Siri A., Ponassi M., Caocci F., Linnala A., Virtanen I., Zardi L. Production and characterization of monoclonal antibodies specific for different epitopes of human tenascin. FEBS Lett. 332:1993;39-43.
24. Paganelli G., Magnani P., Zito F., Villa E., Stella M., Lopalco L., Siccardi A.G., Fazio F. Three-step monoclonal antibody tumor targeting in carcinoembryonic antigen patients. Cancer Res. 51:1991;5960-5966.
25. Riva P., Arista A., Tison V., Sturiale C., Franceschi G., Spinelli A., Riva N., Casi M., Moscatelli G., Frattarelli M. Intralesional radio-immunotherapy of malignant gliomas. Cancer. 73:1994;1076-1082.
26. R.O. Hynes, Fibronectins, Springer-Verlag, New York, 1990.
27. Castellani P., Siri A., Rosellini C., Infusini E., Borsi L., Zardi L. Transformed human cells release different fibronectin variants than do normal cells. J. Cell Biol. 103:1986;1671-1677.
28. Borsi L., Carnemolla B., Castellani P., Rosellini C., Vecchio D., Allemanni G., Chang S.E., Taylor-Papadimitriou J., Pande H., Zardi L. Monoclonal antibodies in the analysis of fibronectin isoforms generated by alternative splicing of mRNA precursors in normal and transformed human cells. J. Cell Biol. 104:1987;595-600.
29. Vartio T., Laitinen L., Narvanen O., Cutolo M., Thornell L.-E., Zardi L., Virtanen I. Differential expression of the ED sequence-containing form of cellular fibronectin in embryonic and adult human tissues. J. Cell Sci. 88:1987;419-430.
30. Zardi L., Carnemolla B., Siri A., Petersen T.E., Paolella G., Sebastio G., Baralle F.E. Transformed human cells produce a new fibronectin isoform by preferential alternative splicing of a previously unobserved exon. EMBO J. 6:1987;2337-2342.
31. Oyama F., Hirohashi S., Shimosato Y., Titani K., Sekiguchi K. Deregulation of alternative splicing of fibronectin pre-mRNA in malignant human liver tumors. J. Biol. Chem. 264:1989;10331-10334.
32. Oyama F., Hirohashi S., Shimosato Y., Titani K., Sekiguchi K. Oncodevelopmental regulation of the alternative splicing of fibronectin pre-messenger RNA in human lung tissues. Cancer Res. 50:1990;1075-1078.
33. Borsi L., Balza E., Allemanni G., Zardi L. Differential expression of the fibronectin isoform containing the ED-B oncofetal domain in normal human fibroblast cell lines originating from different tissues. Exp. Cell Res. 199:1992;98-105.
34. Norton P.A., Hynes R.O. Alternative splicing of chicken fibronectin in embryos and in normal and transformed cells. Mol. Cell. Biol. 7:1987;4297-4307.
35. ffrench-Constant C., Van De Water L., Dvorak H.F., Hynes R.O. Reappearance of an embryonic pattern of fibronectin splicing during wound healing in the adult rat. J. Cell Biol. 109:1989;903-914.
36. ffrench-Constant C., Hynes R.O. Alternative splicing of fibronectin is temporally and spatially regulated in the chicken embryo. Development. 106:1989;375-388.
37. Laitinen L., Vartio T., Virtanen I. Cellular fibronectins are differentially expressed in human fetal and adult kidney. Lab. Invest. 64:1991;492-498.
38. Carnemolla B., Leprini A., Allemanni G., Saginati M., Zardi L. The inclusion of the type III repeat ED-B in the fibronectin molecule generates conformational modifications that unmask a cryptic sequence. J. Biol. Chem. 267:1992;24689-24692.
39. Peters J.H., Trevithick J.E., Johnson P., Hynes R.O. Expression of the alternatively spliced EIIIB segment of fibronectin. Cell Adhesion Commun. 3:1995;67-89.
40. Carnemolla B., Neri D., Castellani P., Leprini A., Neri G., Pini A., Winter G., Zardi L. Phage antibodies with pan-species recognition of the oncofoetal angiogenesis marker fibronectin ED-B domain. Int. J. Cancer. 68:1996;397-405.
41. Huston J.S., Levinson D., Mudgett H.M., Tai M.S., Novotny J., Margolies M.N., Ridge R.J., Bruccoleri R.E., Haber E., Crea R., Oppermann H. Protein engineering of antibody binding sites: recovery of specific activity in an anti-digoxin single-chain Fv analogue produced in Escherichia coli. Proc. Natl. Acad. Sci. USA. 85:1988;5879-5883.
42. Bird R.E., Hardman K.D., Jacobson J.W., Johnson S., Kaufman B.M., Lee S.M., Lee T., Pope S.H., Riordan G.S., Whitlow M. Single-chain antigen-binding proteins. Science. 242:1988;423-426.
43. Crothers D.M., Metzger H. The influence of polyvalency on the binding properties of antibodies. Immunochemistry. 9:1972;341-357.
44. Foote J., Winter G. Antibody framework residues affecting the conformation of the hypervariable loops. J. Mol. Biol. 224:1992;486-499.
45. Clackson T., Hoogenboom H.R., Griffiths A.D., Winter G. Making antibody fragments using phage display libraries. Nature (London). 352:1991;624-628.
46. Krebber A., Bornhauser S., Burmester J., Honeggerm A., Willuda J., Bosshard H.R., Plückthun A. Reliable cloning of functional antibody variable domains from hybridomas and spleen cell repertoires employing a reengineered phage display system. J. Immunol. Methods. 201(1):1997;35-55.
47. Smith G.P. Filamentous fusion phage: novel expression vectors that display cloned antigens on the virion surface. Science. 228:1985;1315-1317.
48. McCafferty J., Griffiths A.D., Winter G., Chiswell D.J. Phage antibodies: filamentous phage displaying antibody variable domains. Nature (London). 348:1990;552-554.
49. Marks J.D., Hoogenboom H.R., Bonnert T.P., McCafferty J., Griffiths A.D., Winter G. By-passing immunization. Human antibodies from V-gene libraries displayed on phage. J. Mol. Biol. 222:1991;581-597.
50. Hoogenboom H.R., Griffiths A.D., Johnson K.S., Chiswell D.J., Hudson P., Winter G. Multi-subunit proteins on the surface of filamentous phage: methodologies for displaying antibody (Fab) heavy and light chains. Nucl. Acids Res. 19:1991;4133-4137.
51. Nissim A., Hoogenboom H.R., Tomlinson I.M., Flynn G., Midgley C., Lane D., Winter G. Antibody reagents from a 'single-pot' phage display library as immunochemical reagents. EMBO J. 13:1994;692-698.
52. Griffiths A.D., Williams S.C., Hartley O., Tomlinson I.M., Waterhouse P., Crosby W.L., Kontermann R.E., Jones P.T., Low N.M., Allison T.J., Prospero T.D., Hoogenboom H.R., Nissim A., Cox J.P.L., Harrison J.L., Zaccolo M., Gherardi E., Winter G. Isolation of high affinity human antibodies directly from large synthetic repertoires. EMBO J. 13:1994;3245-3260.
53. De Kruif J., Terstappen L., Boel E., Logtenberg T. Rapid selection of cell sub population-specific human monoclonal antibodies from a synthetic phage antibody library. Proc. Natl. Acad. Sci. USA. 92:1995;3938-3942.
54. Vaughan T.J., Williams A.J., Pritchard K., Osbourn J.K., Pope A.R., Earnshaw J.C., McCafferty J., Hodits R.A., Wilton J., Johnson K.S. Human antibodies with sub-nanomolar affinities isolated from a large non-immunized phage display library. Nature Biotechnol. 14:1996;309-314.
55. Winter G., Griffiths A.D., Hawkins R.E., Hoogenboom H.R. Making antibodies by phage display technology. Annu. Rev. Immunol. 12:1994;433-455.
56. Hoogenboom H.R., Winter G. Bypassing immunisation: human antibodies from synthetic repertoires of germ line VH-gene segments rearranged in vitro. J. Mol. Biol. 227:1992;381-388.
57. Waterhouse P., Griffiths A.D., Johnson K.S., Winter G. Combinatorial infection and in vivo recombination: a strategy for making large phage antibody repertoires. Nucl. Acids Res. 21:1993;2265-2266.
58. Marks J.D., Griffiths A.D., Malmqvist M., Clackson T.P., Bye J.M., Winter G. By-passing immunization: building high-affinity human antibodies by chain shuffling. Bio/Technology. 10:1992;779-783.
59. Schier R., Bye J., Apell G., McCall A., Adams G.P., Malmqvist M., Weiner L.M., Marks J.D. Isolation of high-affinity monomeric human anti-c-erbB2 single chain Fv using affinity-driven selection. J. Mol. Biol. 255:1996;28-43.
60. Hawkins R.E., Russel S.J., Winter G. Selection of phage antibodies by binding affinity. Mimicking affinity maturation. J. Mol. Biol. 226:1992;889-896.
61. Barbas C.F. III, Hu D., Dunlop N., Sawyer L., Cababa D., Hendry R.M., Nara P.L., Burton D.R. In vitro evolution of a neutralizing human antibody to human immunodeficiency virus type 1 to enhance affinity and broaden strain cross-reactivity. Proc. Natl. Acad. Sci. USA. 91:1994;3809-3813.
62. Low N., Holliger P., Winter G. Mimicking somatic hypermutation: affinity maturation of antibodies displayed on bacteriophage using a bacterial mutator strain. J. Mol. Biol. 260:1996;359-368.
63. Neri D., Montigiani S., Kirkham P.M. Biophysical methods for the determination of antibody-antigen affinities. Trends Biotechnol. 14:1996;465-470.
64. Pack P., Kujau M., Schroeckh U., Knüpfer R., Wenderoth R., Riesenberg D., Plückthun A. Improved bivalent miniantibodies with identical avidity as whole antibodies produced by high cell density fermentation of Escherichia coli. Bio/Technology. 11:1993;1271-1277.
65. Casey J.L., Keep P.A., Chester K.A., Robson L., Hawkins R.E., Begent R.H. Purification of bacterially expressed single chain Fv antibodies for clinical applications using metal chelate chromatography. J. Immunol. Methods. 179:1995;105-116.
66. Begent R.H.J., Verhaar M.J., Chester K.A., Green A.J., Napier M.P., Hope-Stone L.D., Cushen N., Keep P.A., Johnson C.J., Hawkins R.E., Hilson A.J.W., Robson L. Clinical evidence of efficient tumor targeting based on single-chain Fv antibody selected from a combinatorial library. Nature Med. 2:1996;979-984.
67. Begent R.H.J., Chester K.A., Connors T., Crowther D., Fox B., Griffiths E., Hince T.A., Ledermann J.A., McVie J.G., Minor P., Secher D.S., Schwartsmann G., Thorpe R., Wilbin C., Zwierzina H. Cancer Research Campaign operation manual for control recommendations for products derived from recombinant DNA technology prepared for investigational administration to patients in Phase I trials. Eur. J. Cancer. 29A:1993;1907-1910.
68. Huang H., Molema G., King S., Watkins L., Edgington T.S., Thorpe P.E. Tumor infarction in mice by antibody-directed targeting of tissue factor to tumor neo-vasculature. Science. 275:1997;547-550.
69. Trail P.A., Willner D., Lasch S.J., Henderson A.J., Hofstead S., Casazza A.M., Firestone R.A., Hellström I., Hellström K.E. Cure of xenografted human carcinomas by BR96-doxorubicin immunoconjugates. Science. 261:1993;212-215.
70. 131I-B1 (anti-CD20) antibody therapy with autologous stem cell transplantation for relapsed B cell lymphomas. Lancet. 346:1995;336-340.
71. Reiter Y., Brinkmann U., Lee B., Pastan I. Engineering antibody Fv fragments for cancer detection and therapy: disulfide-stabilised Fv fragments. Nature Biotechnol. 14:1996;1239-1245.
72. Thrush G.R., Lark L.R., Clinchy B.C., Vitetta E.S. Immunotoxins: an update. Annu. Rev. Immunol. 14:1996;49-72.
73. Gadina M., Newton D.L., Rybak S.M., Wu Y.N., Youle R.J. Humanized immunotoxins. Ther. Immunol. 1:1994;59-64.
74. Pai L.H., Wittes R., Setser A., Willingham M.C., Pastan I. Treatment of advanced solid tumours with immunotoxin LMB-1: an antibody linked to Pseudomonas exotoxin. Nature Med. 2:1996;350-353.
75. Berthiaume F., Reiken S.R., Toner M., Tomkins R.G., Yarmush M.L. Antibody-targeted photolysis of bacteria in vivo. Bio/Technology. 12:1994;703-706.
76. Bagshawe K.D., Sharma S.K., Springer C.S., Antoniw P. Antibody-directed enzyme prodrug therapy: pilot scale clinical trial. Tumor Target. 1:1995;17-29.
77. Bosslet K., Czech J., Hoffmann D. Tumor-selective prodrug activation by fusion protein-mediated catalysis. Cancer Res. 54:1995;2151-2159.
78. Kerr D.E., Schreiber G.J., Vrudhula V.M., Svensson H.P., Hellström I., Hellström K.E., Senter P.D. Regressions and cures of melanoma xenografts following treatment with monoclonal antibody beta-lactamase conjugates in combination with anticancer prodrugs. Cancer Res. 55:1995;3558-3563.
79. Dohlsten M., Abrahmsen L., Björk P., Lando P.A., Hedlund G., Forsberg G., Brodin T., Gascoigne N.R.J., Förberg C., Lind P., Kalland T. Monoclonal antibody-superantigen fusion proteins: tumor-agents for T-cell-based tumor therapy. Proc. Natl. Acad. Sci. USA. 91:1994;8945-8949.
80. Becker J.C., Pancook J.D., Gillies S.D., Mendelsohn J., Reisfeld R.A. Eradication of human hepatic and pulmonary melanoma metastases in SCID mice by antibody-interleukin 2 fusion proteins. Proc. Natl. Acad. Sci. USA. 93:1996;2702-2707.
81. Savage P., So A., Spooner R.A., Epenetos A.A. A recombinant single-chain antibody interleukin-2 fusion protein. Br. J. Cancer. 67:1993;304-310.
82. Graziano R.F., Tempest P.R., White P., Keler T., Deo Y., Ghebremariam H., Coleman K., Pfefferkorn L.C., Fanger M.W., Guyre P.M. Construction and characterisation of a humanised anti-gamma-Ig receptor type I (Fc gamma RI) monoclonal antibody. J. Immunol. 155:1995;4996-5002.
83. Moreno M.B., Titus J.A., Cole M.S., Tso J.Y., Le N., Paik C.H., Bakacs T., Zarchachuk C.M., Segal D.M., Wunderlich J.R. Bispecific antibodies retarget murine T cell cytotoxicity against syngeneic breast cancer in vitro and in vivo. Cancer Immunol. Immunother. 40:1995;182-190.
84. French R.R., Hamblin T.J., Bell A.J., Tutt A.L., Glennie M.J. Treatment of B-cell lymphomas with a combination of bispecific antibodies and saporin. Lancet. 346:1995;223-224.
85. Hoogenboom H.R. Mix and match. Building manifold binding sites. Nature Biotechnol. 15:1997;125-126.